Inflammasome Signaling in Atrial Fibrillation: JACC State-of-the-Art Review

Amir Ajoolabady; Stanley Nattel; Gregory Y H Lip; Jun Ren

doi:10.1016/j.jacc.2022.03.379

Inflammasome Signaling in Atrial Fibrillation: JACC State-of-the-Art Review

J Am Coll Cardiol. 2022 Jun 14;79(23):2349-2366. doi: 10.1016/j.jacc.2022.03.379.

Authors

Amir Ajoolabady¹, Stanley Nattel², Gregory Y H Lip³, Jun Ren⁴

Affiliations

¹ Shanghai Institute of Cardiovascular Diseases, Department of Cardiology, Zhongshan Hospital Fudan University, Shanghai, China.
² Department of Medicine, Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada; Research Center, Montreal Heart Institute, Montreal, Quebec, Canada; Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada; Institute of Pharmacology, West German Heart and Vascular Center, University of Duisburg-Essen, Essen, Germany; IHU LIYRC Institute, Bordeaux, France.
³ Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. Electronic address: [email protected].
⁴ Shanghai Institute of Cardiovascular Diseases, Department of Cardiology, Zhongshan Hospital Fudan University, Shanghai, China; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington USA. Electronic address: [email protected].

Abstract

As the most prevalent form of arrhythmia, atrial fibrillation (AF) increases the risk of heart failure, thromboembolism, and stroke, contributing to the raising mortality and morbidity in patients with cardiovascular diseases. Despite the multifaceted nature of AF pathogenesis and complexity of AF pathophysiology, a growing body of evidence indicates that the NLRP3 inflammasome activation contributes to onset and progression of AF. Herein, the authors aim at reviewing the current literature on the role of inflammasome signaling in AF pathogenesis, and novel therapeutic options in the management of AF.

Keywords: NLRP3 inflammasome; atrial fibrillation; inflammation; interleukins.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Atrial Fibrillation* / drug therapy
Heart Failure* / etiology
Humans
Inflammasomes
Stroke* / complications
Thromboembolism* / etiology

Substances

Inflammasomes

Grants and funding

CIHR/Canada